05
2024-06
KX-826 Received The INCI Designation
June 5, 2024-Kintor Pharmaceutical Limited announced that KX-826 received the INCI designation.
24
2024-05
Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.
21
2024-04
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
April 21, 2024-Kintor Pharma announced that GT20029 China Phase II Trial For AGA Reached Primary Endpoint.
02
2024-04
AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected
Three oncology studies from kintor pharma selected 2024 American Association of Cancer Research Annual Meeting.
13
2024-03
c-Myc Degrader Study Published in Subsidiary Journal of Nature
c-Myc Degrader Study Published in Subsidiary Journal of Nature. The study shows that c-Myc molecular glue compound has great potential.
28
2023-10
Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn